Rituximab in anti-glomerular basement membrane disease

QJM: An International Journal of Medicine

Volumn 105, Issue 2, 2012, Pages 195-197

  Shah, Y ^a   Mohiuddin, A ^a   Sluman, C ^a   Daryanani, I ^a   Ledson, T ^a   Banerjee, A ^a   Crowe, A ^a   McClelland, P ^a  

^a ARROWE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; ERYTHROMYCIN; HEMOGLOBIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYELOPEROXIDASE; PREDNISOLONE; RITUXIMAB;

ACUTE KIDNEY TUBULE NECROSIS; ADOLESCENT; ADULT; AGGLUTINATION TEST; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIGLOMERULAR BASEMENT MEMBRANE DISEASE; ANURIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ENDOSCOPY; FOLLOW UP; GLOMERULONEPHRITIS; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LETHARGY; LEUKOPENIA; LUNG HEMORRHAGE; MALE; MEAN CORPUSCULAR VOLUME; MULTIPLE SCLEROSIS; NAUSEA; NAUSEA AND VOMITING; NOSE OBSTRUCTION; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; RETICULOCYTE COUNT; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84856112647     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr001     Document Type: Article

References (10)

1. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's Lymphoma. Blood 1997; 90:2188-95.
2. Edwards JC, Szczepanski L, Szechinsski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-8.
3. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase 1/2 dose-escalation trial of rituximab. Arthritis Rheum 2004; 50:2580-9.
4. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salam AD, Smith AD, et al. A multicenter survey of rituximab therapy for refractory anti-neutrophilic cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156-68.
5. Fervernza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73:117-25.
6. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002; 61:922-4.
7. Wechsler E, Yang T, Jordan SC, Vo A, Nast CC. Anti-glomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol 2008; 4:167-71.
8. Levy JB, Turner N, Rees AJ, Pusey CD. Long term outcome of anti-glomerular basement membrane antibody disease with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033-42.
9. Turner N, Mason PJ, Brwon R, Fox M, Povey S, Rees A. Molecular cloning of the human goodpasture antigen demonstrates it to be α 3chain of type 4 collagen. J Clin Invest 1992; 89:592-601.
10. Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999; 56:1638-54.